TIBSOVO Drug Patent Profile

When do Tibsovo patents expire, and when can generic versions of Tibsovo launch?

Tibsovo is a drug marketed by Servier and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-eight patent family members in forty-five countries.

The generic ingredient in TIBSOVO is ivosidenib. One supplier is listed for this compound. Additional details are available on the ivosidenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Tibsovo

Tibsovo was eligible for patent challenges on July 20, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2035. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TIBSOVO

International Patents:	178
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIBSOVO

Paragraph IV (Patent) Challenges for TIBSOVO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TIBSOVO	Tablets	ivosidenib	250 mg	211192	1	2022-07-20

US Patents and Regulatory Information for TIBSOVO

TIBSOVO is protected by thirty-one US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,968,595.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	10,653,710
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes	9,850,277		Y	Y

International Patents for TIBSOVO

When does loss-of-exclusivity occur for TIBSOVO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Israel

Japan

Mexico

Morocco

New Zealand

Philippines

South Korea

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TIBSOVO around the world.

Country	Patent Number	Title	Estimated Expiration
China	102985557	Methods and compositions for cell-proliferation-related disorders
Japan	6067226
Brazil	122024000250
France	23C1031

Supplementary Protection Certificates for TIBSOVO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2804851	PA2023529	Lithuania		PRODUCT NAME: IVOSIDENIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TAUTOMERAS, IZOTOPOLOGAS ARBA HIDRATAS; REGISTRATION NO/DATE: EU/1/23/1728 20230504
2804851	2390027-7	Sweden		PRODUCT NAME: IVOSIDENIB OR A PHARMACEUTICALLY ACCEPTABLE SALT, TAUTOMER, ISOTOPOLOGUE OR HYDRATE THEREOF; REG. NO/DATE: EU/1/23/1728 20230508
2804851	C20230022 00409	Estonia		PRODUCT NAME: IVOSIDENIIB;REG NO/DATE: EU/1/23/1728 08.05.2023
2804851	PA2023529,C2804851	Lithuania		PRODUCT NAME: IVOSIDENIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TAUTOMERAS, IZOTOPOLOGAS ARBA HIDRATAS; REGISTRATION NO/DATE: EU/1/23/1728 20230504

TIBSOVO (Ivosidenib): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

TIBSOVO (ivosidenib) is a targeted therapy approved by the U.S. FDA primarily for treating acute myeloid leukemia (AML) harboring IDH1 mutations. Launched in 2018 by AbbVie and partnered with Roche for global marketing, TIBSOVO has demonstrated significant clinical efficacy, fueling a promising growth forecast driven by expanding indications, increasing prevalence of target patient populations, and strategic geographic expansion. This report analyzes TIBSOVO’s current market landscape, growth prospects, competitive positioning, and financial trajectory to support investment decisions.

---

What Is the Current Investment Landscape for TIBSOVO?

Parameter	Details
Market Cap (2023)	Estimated over $14 billion (public data, via AbbVie), signifying significant investor interest.
Key Players	AbbVie (developer), Roche (co-marketing outside US), partnerships across markets.
FDA Approval Date	May 2018 (for IDH1-mutant relapsed/refractory AML).
Global Market Penetration	Primarily North America, expanding into Europe, Asia, and other territories.
Sales (2022)	~ $285 million worldwide (estimated; AbbVie financials), with forecasted growth driven by expanded indications and pipeline progress.

---

How Do Market Dynamics Influence TIBSOVO's Growth?

1. Disease Market and Patient Demographics

Attribute	Details
Target Condition	Acute Myeloid Leukemia (AML), specifically with IDH1 mutations.
Prevalence	Approx. 20-30% of AML cases (~20,000 new AML diagnoses annually in the US).
Mutation Frequency	IDH1 mutations occur in ~6-8% of AML patients, with higher prevalence among older adults.
Patient Population	Elderly and high-risk patients with relapsed/refractory AML are primary targets; expanding into newly diagnosed setting.

2. Competitive Environment

Competitors	Drugs targeting AML with similar mechanisms:
IDH2 inhibitors	Enasidenib (Idhifa, Eisai).
Other AML therapies	Hypomethylating agents (azacitidine, decitabine), chemotherapy, and emerging immunotherapies.
Market Differentiators	Mutational specificity, oral administration, favorable safety profile, and combination therapy potential.

3. Regulatory and Reimbursement Policies

Policy Factor	Impact
FDA Approvals	Multiple approvals for AML treatment; expanding indications could increase utilization.
Pricing and Reimbursement	Listing prices estimated at ~$21,600 per 100 mg/day; reimbursement policies vary by country. Expansion into commercial markets likely to enhance revenues.
Orphan Drug Designation	Provides market exclusivity and potential regulatory incentives.

4. Market Expansion and Pipeline Potential

• Label Expansion: Approval for newly diagnosed AML with IDH1 mutations (FDA in 2022), broadening the patient pool.
• Other Indications: Investigation in cholangiocarcinoma, gliomas, and other IDH1-mutant tumors.
• Combination Therapies: Trials combining TIBSOVO with chemotherapy, other targeted agents, and immunotherapies; promising for increasing efficacy.

---

What Is the Financial Trajectory of TIBSOVO?

1. Revenue Growth Forecast

Year	Estimated Revenue (USD millions)	Comments
2022	~$285	Existing indications, steady growth.
2023	~$400 - $500	New approvals, expanded patient base, pipeline momentum.
2024+	~$700 - $1,000+	Potential pipeline milestones, geographic expansion.

2. Revenue Drivers

Factor	Impact
Expanded Indications	Newly diagnosed AML approval in 2022 broadens patient base.
Geographic Expansion	Market penetration in Europe, Asia, Latin America.
Pipeline Progress	Ongoing trials in other cancers can create new revenue streams.
Reimbursement Policies	Favorable payer coverage increases access and sales.

3. Cost Structure and Margin Profile

Component	Details
R&D Investment	Significant ongoing expenditure for pipeline and label expansion.
Manufacturing Costs	Moderate, owing to oral formulation.
Gross Margin	Estimated over 70%, consistent with targeted cancer therapies.
Operating Margin	Expected to improve with sales growth and pipeline development.

4. Investment Risks and Mitigation

Risk Factor	Description
Market Competition	Entry of new therapies or generics post-patent expiry.
Regulatory Changes	Delays or denials in approval for new indications.
Clinical Trial Outcomes	Unfavorable results could affect further indications or market expansion.
Pricing & Reimbursement	Payer resistance or policy shifts could impact sales.

---

Comparison of TIBSOVO With Key Competitors

Parameter	TIBSOVO (Ivosidenib)	Idhifa (Enasidenib)	Other AML Therapies
Mechanism	IDH1 inhibitor	IDH2 inhibitor	Chemotherapy, hypomethylating agents
Approval Year	2018	2017	Varies
Indications	AML with IDH1 mutations	AML with IDH2 mutations	Broad AML treatments
Market Cap (2023)	> $14 billion	Data not publicly listed	N/A
Pricing	~$21,600/100 mg daily	Similar, slightly higher	N/A
Pipeline/Expansion	Yes, in other IDH1-mutant cancers	Yes, in other IDH2-mutant cancers	Varies

---

Deep-Dive Into Key Market Segments and Growth Areas

1. Geographic Expansion

• United States: Leading sales, with high adoption for relapsed/refractory AML.
• Europe: Regulatory approvals granted; local pricing negotiations underway.
• Asia-Pacific: Large growth potential, particularly in Japan, China, and South Korea, subject to regulatory approval.

2. Indication Broadening

Existing	Potential Expansion
Relapsed/Refractory AML	Newly diagnosed AML with IDH1 mutations (~60-70% of AML patients).
Specific gene mutations	Other IDH1-mutant neoplasms (cholangiocarcinoma, gliomas).
Combinatory therapies	In combination with other agents for synergy and improved efficacy.

3. Pipeline and Development Focus

Project/Trial	Stage	Potential Impact
Combination with Azacitidine	Phase 3	Improved response rates.
New indications (e.g., cholangiocarcinoma)	Early stage trials	Diversifies revenue sources.
Label expansion for newly diagnosed AML	Approved (2022)	Significant growth driver.

---

Financial Outlook and Investment Considerations

Metrics	2022 Actuals	Forecast 2023-2025
Revenue ($ millions)	~$285	$400M (2023), growing to over $1B by 2025 with pipeline success.
Gross Margin (%)	~70%	Maintains or increases with scale.
Net Profit Margin	Data sparse	Potentially positive with sales growth and pipeline milestones.
Market Cap (USD)	Estimated > $14 billion	Potential to double if expanded indications and geographic penetration materialize.

---

Summary of Strategic Opportunities and Challenges

Opportunities	Challenges
Market expansion into Europe and Asia	Competitive landscape intensifies
Label expansion for newly diagnosed AML	Pricing pressures post-patent expiration
Pipeline progression into other IDH1-mutant neoplasms	Clinical trial failures or delays
Combination therapy adoption	Regulatory hurdles in global markets

---

Key Takeaways

• TIBSOVO operates in a high-growth segment of targeted AML therapies, with revenues expanding due to approved indications, pipeline developments, and geographic expansion.
• The product's success hinges on gaining broader FDA and international approvals, particularly for newly diagnosed AML and other IDH1-mutant indications.
• Strategic partnerships, especially with Roche, provide broad marketing and development support, bolstering sales potential.
• Competitive pressures from emerging therapies and potential generics post-patent expiry pose risks.
• The financial trajectory projects sustained growth, with revenues potentially exceeding $1 billion by 2025 if current expansion strategies succeed.

---

Frequently Asked Questions

1. What are the primary drivers for TIBSOVO’s market growth?

Expansion into newly diagnosed AML, approval in international markets, pipeline development in other IDH1-mutant cancers, and combination therapy trials.

2. How does TIBSOVO compare price-wise to other AML therapies?

Pricing is approximately $21,600 per 100 mg daily; comparable to other targeted agents. Cost-effectiveness and reimbursement policies are key for market penetration.

3. What regulatory hurdles could impact TIBSOVO’s growth?

Delays in approvals for new indications, disagreements on labeling requirements, and reimbursement policies across countries.

4. Which markets offer the most growth potential post-2023?

Europe, China, Japan, and Latin America, driven by increasing AML prevalence and regulatory approvals.

5. How do pipeline prospects influence investment decisions?

Pipeline success in additional indications and combination therapies could significantly enhance long-term value; ongoing trials are critical indicators.

---

Citations

[1] Abbott, AbbVie 2022 Annual Report.
[2] Food and Drug Administration (FDA). TIBSOVO (ivosidenib) NDA approval documents, 2018.
[3] Market research data from Global Data, 2023.
[4] Financial data sources including AbbVie Investor Relations, 2022-2023.
[5] Ongoing clinical trial registry, clinicaltrials.gov.

---

Disclaimer: The above projections and data are based on publicly available information and market analysis as of 2023. Investors should conduct comprehensive due diligence before making any investment decisions.